Hydroxychloroquine in Primary Progressive Multiple Sclerosis

NCT02913157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Primary Progressive

Interventions

DRUG: Hydroxychloroquine

Sponsor

University of Calgary